Table 2.
Summary of changes in disease markers in HIV-infected patients with advanced HCV-related cirrhosis during follow-up.
| HIV/HCV-b | HIV/HCV-f | p-values | q-values | |
|---|---|---|---|---|
| Liver profile | ||||
| LSM (kPa) | 26.7 (18.6; 39.6) | 21.1 (14.1; 31.6) | 0.010 | 0.021 |
| HVPG (mmHg) | 14.5 (10; 17) | 12 (9.5; 14) | 0.030 | 0.047 |
| Bilirubin (mg/dL) | 1.1 (0.8; 1.4) | 0.7 (0.4; 1.1) | <0.001 | 0.001 |
| AST (IU/L) | 70 (37.3; 101.3) | 30 (25.8; 43.5) | 0.006 | 0.016 |
| ALT (IU/L) | 54.5 (30.5; 69.5) | 23 (17.5; 32.5) | <0.001 | <0.001 |
| GGT (IU/L) | 111.5 (73.5; 153) | 45 (30; 62) | 0.002 | 0.007 |
| Alkaline phosphatase (IU/L) | 113 (87.3; 152.5) | 84.5 (57.5; 106) | <0.001 | <0.001 |
| Hematologic profile | ||||
| Leukocytes (106/mL) | 4.2 (3.4; 5.1) | 5.1 (3.5; 6.4) | 0.033 | 0.049 |
| Neutrophils (106/mL) | 2.2 (1.5; 2.7) | 2.6 (2; 3.6) | 0.007 | 0.016 |
| Hematocrit (%) | 41.6 (38.1; 46.8) | 43.1 (40.4; 46.6) | 0.201 | 0.264 |
| Hemoglobin (g/dL) | 14 (12.8; 15.7) | 14.4 (13.2; 15.5) | 0.308 | 0.335 |
| Platelets (109/L) | 80 (52.5; 104.5) | 91 (67.5; 118) | 0.012 | 0.023 |
| Immunologic profile | ||||
| CD4+ T cells (cells/mm3) | 393 (233.5; 806) | 347 (218; 698) | 0.235 | 0.294 |
| CD8+ T cells (cells/mm3) | 610 (376.5; 916) | 609 (357; 928.5) | 0.940 | 0.979 |
| HIV viral load >50 copies/mL (%) | 0/33 (0%) | 0/33 (0%) | 0.999 | 0.999 |
| PD1 (a.u.) | 118.5 (80.8; 147.5) | 61 (46.5; 81.5) | <0.001 | 0.002 |
| PDL1 (a.u.) | 29 (21; 43.3) | 22 (17.5; 38.8) | <0.001 | 0.002 |
| CXCL10 (a.u.) | 1193.5 (771; 1604) | 741.5 (307.8; 994) | <0.001 | 0.002 |
| CXCL8 (a.u.) | 127 (79.5; 188.8) | 73.5 (47; 99.3) | 0.003 | 0.008 |
| CCL2 (a.u.) | 470 (272.8; 677) | 455 (267.5; 644.8) | 0.292 | 0.332 |
| IFNγ (a.u.) | 15 (12; 26) | 16 (13; 23) | 0.285 | 0.332 |
| IL12p70 (a.u.) | 12 (10.3; 14.3) | 11 (9; 13) | 0.024 | 0.040 |
| IL2 (a.u.) | 11 (9.3; 12.5) | 10 (8.8; 12.5) | 0.053 | 0.074 |
| IL10 (a.u.) | 37 (28.8; 46.8) | 29 (25.3; 34.5) | 0.020 | 0.036 |
| TGFβ (a.u.) | 12.2 (8.9; 18.7) | 8.6 (6.7; 14.2) | 0.001 | 0.004 |
Values are expressed as median (P25th; P75th). Differences were calculated by Wilcoxon signed-rank test for paired samples. P-values, raw p-values; q-values, p-values corrected for multiple testing using the false discovery rate (FDR) with Benjamini and Hochberg procedure. The statistically significant differences are shown in bold.
HCV, hepatitis C virus; HIV, human immunodeficiency virus; HIV/HCV-b, HIV/HCV-coinfected at baseline; HIV/HCV-f, HIV/HCV-coinfected at week 36 after SVR; LSM, liver stiffness measure; kPa, kilopascal; HVPG, hepatic venous pressure gradient; mmHg, millimeter of mercury; AST, aspartate transaminase; ALT, alanine aminotransferase; GGT, gamma-glutamyl transpeptidase; g, gram; mg, milligram; L, liter, dL, deciliter; mL, milliliter; IU, international unit; a.u., arbitrary units of fluorescence; PDL1, programmed death-ligand 1; PD1, programmed death-1; CXCL10, C-X-C Motif Chemokine Ligand 10; CXCL8, C-X-C Motif Chemokine Ligand 8; CCL2, C-C Motif Chemokine Ligand 2; IFNγ, interferon-gamma; IL, interleukin; TGFβ, transforming growth factor-beta.